ReveraGen BioPharma

ReveraGen BioPharma is a pioneering biotech that has successfully developed and gained regulatory approval for vamorolone, a first-in-class dissociative steroid for Duchenne muscular dystrophy. The company achieved this milestone through an innovative venture philanthropy and public-private partnership model, operating with an exceptionally lean team. Its focus remains on leveraging its steroid chemistry expertise to create safer anti-inflammatory treatments for rare diseases with high unmet need.

Dissociative steroidal therapeutics designed to separate anti-inflammatory efficacy from typical steroid side effects via partial glucocorticoid receptor agonism.

In DMD, vamorolone competes directly with generic prednisone and deflazacort, which are cheap but have severe side effects. It also competes with novel genetic therapies (e.g., Sarepta's Elevidys) and other anti-inflammatory modalities. Its key differentiation is its first-in-class dissociative mechanism aiming to offer efficacy with a better tolerability profile.